National Institute of Allergy and Infectious Diseases (NIAID), 14 January 2016
Dengue fever is common in many parts of the tropics and subtropics and about half the world’s population is at risk of infection. A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Earlier clinical trials of this candidate conducted in the United States by NIAID showed that it could elicit a robust antibody and cellular immune response after just one dose. Although the trial is scheduled to last five years, the investigators hope to have early indications of the potential efficacy of the vaccine in less than two years.